Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ:OLMA
Want to see OLMA full AI Analyst Report?
Top Page
Olema Pharmaceuticals
(NASDAQ:OLMA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$10.00
▼(-40.55% Downside)
Action:Reiterated
Date:05/27/26
The score is weighed down primarily by weak financial performance (no revenue, expanding losses, and high cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate catalysts (Bayer collaboration and encouraging early OP-3136 data) and a low-debt balance sheet provide partial offset, but valuation signals remain limited due to ongoing losses and no dividend.
Positive Factors
Low-leverage balance sheet
Extremely low leverage and materially expanded equity provide durable financial flexibility for a pre-revenue biotech. This reduces near-term refinancing risk, supports multi-year R&D spend, and preserves optionality for strategic partnerships or staged commercialization even as programs progress toward registrational readouts.
Negative Factors
Pre-revenue, widening net losses
Being wholly pre-revenue with rapidly widening net losses materially increases funding dependency. Until commercialization or meaningful partner income occurs, losses undermine sustainable margin metrics and require continued financing decisions that can dilute equity and compress long-term shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Extremely low leverage and materially expanded equity provide durable financial flexibility for a pre-revenue biotech. This reduces near-term refinancing risk, supports multi-year R&D spend, and preserves optionality for strategic partnerships or staged commercialization even as programs progress toward registrational readouts.
Read all positive factors
Olema Pharmaceuticals (OLMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$900.55M
Dividend YieldN/A
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth-3.83%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.02
Shares Outstanding87,347,470
10 Day Avg. Volume1,500,461
30 Day Avg. Volume1,194,201
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.60K
Enterprise Value/Ebitda-5.57
Forecast
1Y Price Target
$39.44Price Target Upside134.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$2.05M
Olema Pharmaceuticals Business Overview & Revenue Model
Company Description
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the ...
How the Company Makes Money
null...
Olema Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -197.67M | -178.21M | -141.87M | -104.58M | -106.63M | -71.33M |
| Net Income | -185.15M | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
Balance Sheet | ||||||
| Total Assets | 530.64M | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Cash, Cash Equivalents and Short-Term Investments | 505.35M | 505.44M | 434.09M | 261.81M | 204.42M | 287.25M |
| Total Debt | 956.00K | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Total Liabilities | 50.17M | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Stockholders Equity | 480.48M | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
Cash Flow | ||||||
| Free Cash Flow | -148.72M | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
| Operating Cash Flow | -148.72M | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Investing Cash Flow | -106.15M | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Financing Cash Flow | 256.78M | 211.30M | 268.82M | 133.41M | 476.00K | 1.39M |
Olema Pharmaceuticals Technical Analysis
Negative
16.82
Price Trends
14.31
Negative
18.19
Negative
16.89
Negative
Market Momentum
-1.20
Positive
23.67
Positive
6.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLMA, the sentiment is Negative. The current price of 16.82 is above the 20-day moving average (MA) of 12.74, above the 50-day MA of 14.31, and below the 200-day MA of 16.89, indicating a bearish trend. The MACD of -1.20 indicates Positive momentum. The RSI at 23.67 is Positive, neither overbought nor oversold. The STOCH value of 6.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OLMA.
Olema Pharmaceuticals Risk Analysis
Olema Pharmaceuticals disclosed 91 risk factors in its most recent earnings report. Olema Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Olema Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $841.82M | -6.13 | 474.91% | ― | 131.13% | 35.61% | |
53 Neutral | $197.92M | -4.37 | -17.04% | ― | -84.55% | -1998.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $478.75M | ― | -44.39% | ― | -79.06% | -397.92% | |
46 Neutral | $900.55M | ― | -45.95% | ― | ― | -3.83% | |
45 Neutral | $363.78M | -5.52 | -39.75% | ― | -100.00% | -2.72% | |
42 Neutral | $38.87M | -0.21 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
OLMA
Olema Pharmaceuticals
9.96
5.58
127.40%
MGTX
Meiragtx Holdings
9.09
2.77
43.83%
ARVN
Arvinas Holding Company
7.15
-0.68
-8.68%
GOSS
Gossamer Bio
0.17
-1.17
-87.59%
KROS
Keros Therapeutics
10.00
-4.09
-29.03%
CMPX
Compass Therapeutics
2.02
-0.55
-21.40%
Olema Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Olema, Bayer launch OP-3136 prostate cancer collaboration
Positive
May 26, 2026
On May 26, 2026, Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to test its investigational KAT6 inhibitor OP-3136 in combination with Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in meta...
Business Operations and StrategyProduct-Related Announcements
Olema Highlights Encouraging OP-3136 Phase 1 Oncology Results
Positive
May 21, 2026
On May 21, 2026, Olema Oncology reported preliminary Phase 1 data for OP-3136, an oral KAT6 inhibitor, in heavily pretreated patients with ER+/HER2- advanced breast cancer, metastatic castration-resistant prostate cancer, and metastatic non-small ...
Business Operations and Strategy
Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point
Neutral
May 1, 2026
On April 27, 2026, Olema Pharmaceuticals entered into a seven-year lease with KR Oyster Point II, LLC for about 38,176 square feet of office space across the fourth and fifth floors of a building at Oyster Point, with plans to relocate its corpora...
Business Operations and StrategyExecutive/Board Changes
Olema Pharmaceuticals Adds Veteran Director to Support Growth
Positive
Apr 29, 2026
Olema Oncology, the operating name of Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers, with its lead drug palazestrant in two Phase 3 tri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.